Kalaris Therapeutics, Inc.
KLRS
$3.48
-$0.06-1.70%
NASDAQ
| 03/31/2025 | |||||
|---|---|---|---|---|---|
| Net Income | -199.27% | ||||
| Total Depreciation and Amortization | -- | ||||
| Total Amortization of Deferred Charges | -76.54% | ||||
| Total Other Non-Cash Items | 31.95% | ||||
| Change in Net Operating Assets | 213.01% | ||||
| Cash from Operations | -64.59% | ||||
| Capital Expenditure | -- | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | -- | ||||
| Cash from Investing | -- | ||||
| Total Debt Issued | 50.21% | ||||
| Total Debt Repaid | -- | ||||
| Issuance of Common Stock | -- | ||||
| Repurchase of Common Stock | -- | ||||
| Issuance of Preferred Stock | -- | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | 1,995,440.00% | ||||
| Cash from Financing | 1,530.45% | ||||
| Foreign Exchange rate Adjustments | -- | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | 4,750.63% | ||||